Related Experiment Video
Updated: Aug 14, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Targeting stathmin in prostate cancer
Sucharita J Mistry1, Alexander Bank, George F Atweh
1Division of Hematology-Oncology, Department of Medicine, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA. sucharita.mistry@mssm.edu
Abstract:
Stathmin is the founding member of a family of microtubule-destabilizing proteins that regulate the dynamics of microtubule polymerization and depolymerization. Stathmin is expressed at high levels in a variety of human cancers and provides an attractive molecule to target in cancer therapies that disrupt the mitotic apparatus. We developed replication-deficient bicistronic adenoviral vectors that coexpress green fluorescent protein and ribozymes that target stathmin mRNA. The therapeutic potential of these recombinant adenoviruses was tested in an experimental androgen-independent LNCaP prostate cancer model. Adenovirus-mediated transfer of anti-stathmin ribozymes resulted in efficient transduction and marked inhibition of stathmin expression in these cells. Cells that were transduced with the anti-stathmin adenoviruses showed a dramatic dose-dependent growth inhibition. This was associated with accumulation of LNCaP cells in the G2-M phases of the cell cycle. A similar dose-dependent inhibition of clonogenic potential was also observed in cells infected with anti-stathmin adenoviruses. Morphologic and biochemical analysis of infected cells showed a marked increase in apoptosis characterized by detachment of the cells, increased chromatin condensation, activation of caspase-3, and fragmentation of internucleosomal DNA. If these findings are confirmed in vivo, it may provide an effective approach for the treatment of prostate cancer.
Insights
Researchers developed adenoviral vectors targeting stathmin mRNA to inhibit prostate cancer cell growth. This approach effectively reduced stathmin expression, induced apoptosis, and halted cancer cell proliferation, offering a potential new therapy.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Stathmin is a key microtubule-destabilizing protein overexpressed in many cancers.
- Targeting stathmin offers a potential strategy for cancer therapy by disrupting mitosis.
Purpose of the Study:
- To evaluate the therapeutic potential of adenoviral vectors expressing anti-stathmin ribozymes in prostate cancer.
- To assess the impact of stathmin inhibition on cancer cell growth, cell cycle, and apoptosis.
Main Methods:
- Development of replication-deficient bicistronic adenoviral vectors coexpressing GFP and anti-stathmin ribozymes.
- Testing in an androgen-independent LNCaP prostate cancer model.
- Analysis of stathmin expression, cell growth, cell cycle, clonogenic potential, and apoptosis.
Main Results:
- Efficient transduction and significant inhibition of stathmin expression in LNCaP cells.
- Dose-dependent growth inhibition and G2-M cell cycle arrest.
- Induction of apoptosis, evidenced by caspase-3 activation and DNA fragmentation.
Conclusions:
- Adenovirus-mediated delivery of anti-stathmin ribozymes demonstrates potent anti-cancer effects in vitro.
- Stathmin inhibition via gene therapy is a promising strategy for prostate cancer treatment.
- Further in vivo studies are warranted to confirm therapeutic efficacy.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:10Drugs that Destabilize Microtubules